1. Home
  2. INVA vs FTRE Comparison

INVA vs FTRE Comparison

Compare INVA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innoviva Inc.

INVA

Innoviva Inc.

HOLD

Current Price

$23.47

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$10.31

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INVA
FTRE
Founded
1996
1996
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
INVA
FTRE
Price
$23.47
$10.31
Analyst Decision
Buy
Buy
Analyst Count
6
10
Target Price
$36.50
$15.50
AVG Volume (30 Days)
762.5K
1.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.23
$3.21
Revenue Next Year
$8.58
$0.25
P/E Ratio
$15.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.52
$3.97
52 Week High
$23.91
$18.67

Technical Indicators

Market Signals
Indicator
INVA
FTRE
Relative Strength Index (RSI) 80.33 27.78
Support Level $22.12 $9.42
Resistance Level $23.42 $15.00
Average True Range (ATR) 0.73 1.33
MACD 0.30 -0.70
Stochastic Oscillator 91.42 13.88

Price Performance

Historical Comparison
INVA
FTRE

About INVA Innoviva Inc.

Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: